Randomised controlled clinical trial for autologous fibroblast-hyaluronic acid complex in treating diabetic foot ulcers

Journal of Wound Care

Volumn 23, Issue 11, 2014, Pages 521-530

  You, H J ^a   Han, S K ^a   Rhie, J W ^b  

^a Korea University College of Medicine   (South Korea)

^b The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Diabetic foot; Diabetic foot ulcer; Fibroblast; Hyaluronic acid; Wound healing

Indexed keywords

HYALURONIC ACID;

AGED; AUTOGRAFT; AUTOTRANSPLANTATION; BANDAGE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC FOOT; FEMALE; FIBROBLAST; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TRANSPLANTATION; TREATMENT OUTCOME; WOUND HEALING;

AGED; AUTOGRAFTS; BANDAGES; DIABETIC FOOT; FEMALE; FIBROBLASTS; HUMANS; HYALURONIC ACID; MALE; MIDDLE AGED; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; WOUND HEALING;

EID: 84911417493     PISSN: 09690700     EISSN: 20522916     Source Type: Journal    
DOI: 10.12968/jowc.2014.23.11.521     Document Type: Article

References (23)

1. Papanas, N., Eleftheriadou, I., Tentolouris, N., Maltezos, E. Advances in the topical treatment of diabetic foot ulcers. Curr Diabetes Rev 2012; 8: 3, 209-218.
2. Marston, W.A., Hanft, J., Norwood, P., Pollak, R. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care 2003; 26: 6, 1701-1705.
3. You, H.J., Han, S.K., Lee, J.W., Chang, H. Treatment of diabetic foot ulcers using cultured allogeneic keratinocytes-a pilot study. Wound Repair Regen 2012; 20: 4, 491-499.
4. De Loecker, W., Koptelov, V.A., Grischenko, V.I., De Loecker, P. Effects of cell concentration on viability and metabolic activity during cryopreservation. Cryobiology. 1998; 37: 2, 103-109.
5. Kano, M., Masuda, Y., Tominaga, T. et al. Collagen synthesis and collagenase activity of cryopreserved heart valves. J Thorac Cardiovasc Surg 2001; 122: 4, 706-711.
6. Liu, K., Yang, Y., Mansbridge, J. Comparison of the stress response to cryopreservation in monolayer and three-dimensional human fibroblast cultures: stress proteins, MAP kinases, and growth factor gene expression. Tissue Eng 2000; 6: 5, 539-554.
7. Han, S.K., Kim, H.S., Kim, W.K. Efficacy and safety of fresh fibroblast allografts in the treatment of diabetic foot ulcers. Dermatol Surg 2009; 35: 9, 1342-1348.
8. Han, S.K., Choi, K.J., Kim, W.K. Clinical application of fresh fibroblast allografts for the treatment of diabetic foot ulcers: a pilot study. Plast Reconstr Surg 2004; 114: 7, 1783-1789.
9. Wong, T., McGrath, J.A., Navsaria, H. The role of fibroblasts in tissue engineering and regeneration. Br J Dermatol 2007; 156: 6, 1149-1155.
10. Caravaggi, C., De Giglio, R., Pritelli, C. et al. HYAFF 11-based autologous dermal and epidermal grafts in the treatment of noninfected diabetic plantar and dorsal foot ulcers: a prospective, multicenter, controlled, randomized clinical trial. Diabetes Care 2003; 26: 10, 2853-2859.
11. Cavallini, M. Autologous fibroblasts to treat deep and complicated leg ulcers in diabetic patients. Wound Repair Regen 2007; 15: 1, 35-38.
12. Uccioli, L. A clinical investigation on the characteristics and outcomes of treating chronic lower extremity wounds using the tissuetech autograft system. Int J Low Extrem Wounds. 2003; 2: 3, 140-151.
13. Uccioli, L., Giurato, L., Ruotolo, V. et al. Two-step autologous grafting using HYAFF scaffolds in treating difficult diabetic foot ulcers: results of a multicenter, randomized controlled clinical trial with long-term follow-up. Int J Low Extrem Wounds 2011; 10: 2, 80-85.
14. Wagner, F.W., Jr. The diabetic foot. Orthopedics 1987; 10: 1, 163-172.
15. Armstrong, D.G., Lavery, L.A., Harkless, L.B. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care 1998; 21: 5, 855-859.
16. Gary Sibbald, R., Woo, K.Y. The biology of chronic foot ulcers in persons with diabetes. Diabetes Metab Res Rev 2008; 24: Supple 1, S25-30.
17. Warriner, R.A., 3rd, Cardinal, M. Human fibroblast-derived dermal substitute: results from a treatment investigational device exemption (TIDE) study in diabetic foot ulcers. Adv Skin Wound Care 2011; 24: 7, 306-311.
18. Lev-Tov, H., Li, C.S., Dahle, S., Isseroff, R.R. Cellular versus acellular matrix devices in treatment of diabetic foot ulcers: study protocol for a comparative efficacy randomized controlled trial. Trials 2013; 14: 8.
19. Tsourdi, E., Barthel, A., Rietzsch, H. et al. Current aspects in the pathophysiology and treatment of chronic wounds in diabetes mellitus. BioMed Res Int 2013; 2013: 385641.
20. Marston, W.A. Dermagraft, a bioengineered human dermal equivalent for the treatment of chronic nonhealing diabetic foot ulcer. Expert Rev Med Devices 2004; 1: 1, 21-31.
21. Steinberg, J.S., Edmonds, M., Hurley, D.P., Jr., King, W.N. Confirmatory data from EU study supports Apligraf for the treatment of neuropathic diabetic foot ulcers. J Am Podiatr Med Assoc 2010; 100: 1, 73-77.
22. Morimoto, N., Saso, Y., Tomihata, K. et al. Viability and function of autologous and allogeneic fibroblasts seeded in dermal substitutes after implantation. J Surg Res 2005; 125: 1, 56-67.
23. Moura, L.I., Dias, A.M., Carvalho, E., de Sousa, H.C. Recent advances on the development of wound dressings for diabetic foot ulcer treatment-A review. Acta biomater 2013; 9: 7, 7093-7114.